Targeted radionuclide therapy in combined-modality regimens.
about
Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases.[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application].A three-in-one-bullet for oesophageal cancer: replication fork collapse, spindle attachment failure and enhanced radiosensitivity generated by a ruthenium(ii) metallo-intercalator.111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells.Uniform intratumoral distribution of radioactivity produced using two different radioagents, 64Cu-cyclam-RAFT-c(-RGDfK-)4 and 64Cu-ATSM, improves therapeutic efficacy in a small animal tumor model.Subcellular Targeting of Theranostic Radionuclides
P2860
Targeted radionuclide therapy in combined-modality regimens.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Targeted radionuclide therapy in combined-modality regimens.
@en
type
label
Targeted radionuclide therapy in combined-modality regimens.
@en
prefLabel
Targeted radionuclide therapy in combined-modality regimens.
@en
P1433
P1476
Targeted radionuclide therapy in combined-modality regimens
@en
P2093
Nadia Falzone
P304
P356
10.1016/S1470-2045(17)30379-0
P577
2017-07-01T00:00:00Z